We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
+14.32%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
-$724M
(-23%)
Cap. Flow
-$938M
Cap. Flow
% of AUM
-37.88%
Top 10 Holdings %
Top 10 Hldgs %
48.15%
Holding
67
New
27
Increased
10
Reduced
11
Closed
18
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$95.9M |
| 2 |
AGN
Allergan plc
AGN
|
+$89.6M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$62.5M |
| 4 |
Centene
CNC
|
+$61.7M |
| 5 |
UnitedHealth
UNH
|
+$55.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$165M |
| 2 |
CVS Health
CVS
|
+$144M |
| 3 |
LivaNova
LIVN
|
+$139M |
| 4 |
Intuitive Surgical
ISRG
|
+$135M |
| 5 |
CELG
Celgene Corp
CELG
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 87.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Danaher
DHR
$138B
| $139M | 5.6% |
1,185,212
-511,018
| -30% | -$52.4M |
|
|
2
UnitedHealth
UNH
$383B
| $138M | 5.56% |
556,560
+219,280
| +65% | +$55.9M |
|
|
3
Zimmer Biomet
ZBH
$18.4B
| $136M | 5.49% |
1,095,086
+843,564
| +335% | +$95.9M |
|
4
Medtronic
MDT
$110B
| $134M | 5.41% |
1,469,190
-3,600
| -0.2% | -$322K |
|
|
5
Neurocrine Biosciences
NBIX
$18.7B
| $134M | 5.4% |
1,516,090
+747,460
| +97% | +$62.5M |
|
6
Haemonetics
HAE
$3.85B
| $119M | 4.8% |
1,357,410
+257,270
| +23% | +$23.4M |
|
7
Madrigal Pharmaceuticals
MDGL
$11.4B
| $112M | 4.51% |
891,990
+203,100
| +29% | +$25.2M |
|
8
Merck
MRK
$321B
| $105M | 4.22% |
1,317,137
+663,101
| +101% | +$49.6M |
|
|
AGN
9
DELISTED
Allergan plc
AGN
| $90.4M | 3.65% |
+617,760
| New | +$89.6M |
|
10
DexCom
DXCM
$28.8B
| $87M | 3.51% |
2,920,400
-2,954,608
| -50% | -$104M |
|
|
XENT
11
DELISTED
Intersect ENT, Inc
XENT
| $82.7M | 3.34% |
2,571,910
+81,800
| +3% | +$2.53M |
|
|
12
Intuitive Surgical
ISRG
$126B
| $76.9M | 3.1% |
404,070
-759,690
| -65% | -$135M |
|
|
RDUS
13
DELISTED
Radius Health, Inc.
RDUS
| $73.4M | 2.97% |
3,680,949
-43,000
| -1% | -$784K |
|
14
Humana
HUM
$44B
| $68.7M | 2.77% |
258,140
+193,310
| +298% | +$55.7M |
|
15
Vertex Pharmaceuticals
VRTX
$122B
| $62.3M | 2.52% |
338,770
+145,960
| +76% | +$27M |
|
16
IQVIA
IQV
$39.1B
| $57.9M | 2.34% |
402,840
-367,710
| -48% | -$49M |
|
17
Icon
ICLR
$12.8B
| $55.8M | 2.26% |
+408,730
| New | +$55.7M |
|
|
18
Centene
CNC
$30.1B
| $54M | 2.18% |
+1,016,400
| New | +$61.7M |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $52.6M | 2.13% |
+1,991,329
| New | +$47.2M |
|
20
Boston Scientific
BSX
$68.4B
| $49.8M | 2.01% |
1,296,960
-497,650
| -28% | -$19M |
|
|
BLUE
21
DELISTED
bluebird bio
BLUE
| $47.7M | 1.93% |
+23,383
| New | +$41.2M |
|
22
PUT
Stryker
SYK
$133B
| $47.4M | 1.92% |
+240,000
| New | +$43.2M |
|
23
Thermo Fisher Scientific
TMO
$214B
| $43.1M | 1.74% |
+157,520
| New | +$39.2M |
|
24
Becton Dickinson
BDX
$45.6B
| $41.3M | 1.67% |
+169,453
| New | +$40.1M |
|
25
Gilead Sciences
GILD
$163B
| $40.5M | 1.64% |
+623,490
| New | +$41.4M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q1 2019 Portfolio in Review
As of Q1 2019, HealthCor Management held 67 positions worth $2.48B, down 23% from $3.2B the previous quarter. Its ten largest holdings account for 48% of the portfolio.
HealthCor Management withdrew a net $938M in Q1 2019, closing 18 positions and reducing 11 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $165M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 75% a quarter earlier.
Against the trend, HealthCor Management opened a new position in Allergan plc worth $90.4M.
- HealthCor Management's largest Q1 2019 buy was Allergan plc: 617,760 shares worth $90.4M.
- HealthCor Management added most to Zimmer Biomet in Q1 2019, an estimated $95.9M increase.
- HealthCor Management's biggest Q1 2019 reduction was Intuitive Surgical, cutting an estimated $135M.
- HealthCor Management fully exited Regeneron Pharmaceuticals in Q1 2019, selling an estimated $165M.
- HealthCor Management's ten largest holdings make up 48% of its $2.48B portfolio in Q1 2019.
- HealthCor Management opened 27 new positions and closed 18 in Q1 2019.
- HealthCor Management's portfolio value fell 23% quarter-over-quarter to $2.48B.
Based on HealthCor Management's 13F filing for Q1 2019, filed 15 May 2019.